Literature DB >> 12473238

Experimental autoimmune encephalomyelitis: CC chemokine receptor expression by trafficking cells.

Andrzej R Glabinski1, Bartosz Bielecki, Sage O'Bryant, Krzysztof Selmaj, Richard M Ransohoff.   

Abstract

Chemokines are chemotactic cytokines, which stimulate migration of inflammatory cells towards tissue sites of inflammation. The largest chemokine group, termed CC chemokines (CCLs), act primarily on T cells and monocytes, through CC chemokine receptors (CCRs) belonging to the superfamily of G-protein coupled seven transmembrane domain receptors. CCR expression is a critical determinant of cellular responses to CCLs. In this report, we describe the expression pattern of mRNA encoding selected CCRs in the spinal cord and spleen of perfused and non-perfused mice at different stages of chronic-relapsing EAE (ChREAE). We detected increased expression of receptors (CCR1, CCR5) associated with T helper-1 (Th1) but not those (CCR3, CCR4) associated with Th2 T cells in spinal cord during initial attack and relapse of ChREAE. Expression of these CCRs correlated temporally and spatially with reported previously expression of corresponding CCLs. The principal cells expressing CCR5 were inflammatory cells invading the spinal cord. Our results supported the implication of Th1-associated CCRs in the CNS-specific inflammatory reaction of ChREAE.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12473238     DOI: 10.1006/jaut.2002.0613

Source DB:  PubMed          Journal:  J Autoimmun        ISSN: 0896-8411            Impact factor:   7.094


  9 in total

Review 1.  G protein-coupled receptors as therapeutic targets for multiple sclerosis.

Authors:  Changsheng Du; Xin Xie
Journal:  Cell Res       Date:  2012-06-05       Impact factor: 25.617

Review 2.  Trafficking of immune cells in the central nervous system.

Authors:  Emma H Wilson; Wolfgang Weninger; Christopher A Hunter
Journal:  J Clin Invest       Date:  2010-05-03       Impact factor: 14.808

3.  Soluble mannosylated myelin peptide inhibits the encephalitogenicity of autoreactive T cells during experimental autoimmune encephalomyelitis.

Authors:  Junda Kel; Judith Oldenampsen; Mariken Luca; Jan Wouter Drijfhout; Frits Koning; Lex Nagelkerken
Journal:  Am J Pathol       Date:  2007-01       Impact factor: 4.307

Review 4.  Role of CCR2 in inflammatory conditions of the central nervous system.

Authors:  Hannah X Chu; Thiruma V Arumugam; Mathias Gelderblom; Tim Magnus; Grant R Drummond; Christopher G Sobey
Journal:  J Cereb Blood Flow Metab       Date:  2014-07-02       Impact factor: 6.200

5.  Myelin-specific regulatory T cells accumulate in the CNS but fail to control autoimmune inflammation.

Authors:  Thomas Korn; Jayagopala Reddy; Wenda Gao; Estelle Bettelli; Amit Awasthi; Troels R Petersen; B Thomas Bäckström; Raymond A Sobel; Kai W Wucherpfennig; Terry B Strom; Mohamed Oukka; Vijay K Kuchroo
Journal:  Nat Med       Date:  2007-03-25       Impact factor: 53.440

Review 6.  Role of IL-17 and Th17 cells in liver diseases.

Authors:  Linda Hammerich; Felix Heymann; Frank Tacke
Journal:  Clin Dev Immunol       Date:  2010-12-15

7.  CD4+c-Met+Itgα4+ T cell subset promotes murine neuroinflammation.

Authors:  Mahdia Benkhoucha; Ngoc Lan Tran; Gautier Breville; Isis Senoner; Paul F Bradfield; Thalia Papayannopoulou; Doron Merkler; Thomas Korn; Patrice H Lalive
Journal:  J Neuroinflammation       Date:  2022-04-29       Impact factor: 9.587

8.  Clozapine reduces infiltration into the CNS by targeting migration in experimental autoimmune encephalomyelitis.

Authors:  Katharina Robichon; Vimal Patel; Bronwen Connor; Anne Camille La Flamme
Journal:  J Neuroinflammation       Date:  2020-02-12       Impact factor: 8.322

9.  Recruitment of γδ T cells to the lesion via the CCL2/CCR2 signaling after spinal cord injury.

Authors:  Ping Xu; Feng Zhang; Min-Min Chang; Cheng Zhong; Cheng-Hong Sun; Hao-Ran Zhu; Jing-Chun Yao; Zhi-Zhong Li; Si-Tao Li; Wen-Cai Zhang; Guo-Dong Sun
Journal:  J Neuroinflammation       Date:  2021-03-02       Impact factor: 8.322

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.